Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation

Nicola A Hanania; Jorge F Maspero; David M G Halpin; David J Jackson; Reynold A Panettieri; Mario Castro; Christian Domingo; Nadia Daizadeh; Rebecca Gall; Juby A Jacob-Nara; Benjamin Ortiz; Michel Djandji; Paul J Rowe; Yamo Deniz

doi:10.2147/JAA.S354013

Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation

J Asthma Allergy. 2022 Jun 28:15:851-854. doi: 10.2147/JAA.S354013. eCollection 2022.

Authors

Nicola A Hanania¹, Jorge F Maspero², David M G Halpin³, David J Jackson^{4

5}, Reynold A Panettieri⁶, Mario Castro⁷, Christian Domingo⁸, Nadia Daizadeh⁹, Rebecca Gall¹⁰, Juby A Jacob-Nara¹¹, Benjamin Ortiz¹⁰, Michel Djandji⁹, Paul J Rowe¹¹, Yamo Deniz¹⁰

Affiliations

¹ Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA.
² Fundación CIDEA, Buenos Aires, Argentina.
³ University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
⁴ School of Immunology and Microbial Sciences, King's College London, London, UK.
⁵ Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.
⁶ Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
⁷ University of Kansas School of Medicine, Kansas City, KS, USA.
⁸ Pulmonary Service, Corporació Sanitària Parc Taulí, Sabadell, Autonomous University of Barcelona, Barcelona, Spain.
⁹ Sanofi, Cambridge, MA, USA.
¹⁰ Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
¹¹ Sanofi, Bridgewater, NJ, USA.

No abstract available

Grants and funding

Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT02414854. Medical writing/editorial assistance was provided by Natalia Crespo, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.